CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection
Status:
Completed
Trial end date:
2020-07-25
Target enrollment:
Participant gender:
Summary
The overall objective of the study is to determine the therapeutic effect and tolerance of
Anakinra in patients with moderate, severe pneumonia or critical pneumonia associated with
Coronavirus disease 2019 (COVID-19). Anakinra (ANA) is a recombinant human decoy IL-1Ra and
therefore blocks IL-1α and IL-1β. The study has a cohort multiple Randomized Controlled
Trials (cmRCT) design. Randomization will occur prior to offering Anakinra administration to
patients enrolled in the COVIMUNO-19 cohort. Anakinra will be administered to consenting
adult patients hospitalized with CORVID-19 either diagnosed with moderate or severe pneumonia
requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation.
Patients who will chose not to receive Anakinra will receive standard of cares. Outcomes of
Anakinra -treated patients will be compared with outcomes of standard of care treated
patients as well as outcomes of patients treated with other immune modulators.